Group B Streptococcal Infection
11
0
0
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
9.1%
1 terminated out of 11 trials
83.3%
-3.2% vs benchmark
0%
0 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (11)
Immunogenicity and Safety of GBS-NN/NN2 in Pregnant Women
Comprehensive Outcomes Monitoring for Peri- and Postnatal Invasive Group B Strep Sequelae (COMPPASS) Registry
Group B Streptococcus Infection and PROM Incidince
Clinical Trial Investigating the Safety and Immunogenicity of GBS6 in Pregnant Women With and Without HIV (PREPARE)
Study of a Group B Streptococcus Vaccine in Pregnant Women Living With HIV and in Pregnant Women Who do Not Have HIV
MATERNAL AND NEONATAL SCREENING FOR GROUP B STREPTOCOCCI : A Follow up STUDY
Time Frame for GBS Screening
Intrapartum Effect of Vancomycin on Rectovaginal GBS Colonization
Simplified GBS Screening and Prevalence of ESBL in Pregnant Women
Oral Probiotics Reduce Group B Streptococci Colonization in Pregnant Women
Effect of Probiotics on GBS Colonization Status During Pregnancy: A Pilot Randomized Controlled Trial